Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ ...
Actual results may vary in a material nature from those expressed or implied by the statements herein due to changes in economic, business, competitive, and/or regulatory factors, and other risks and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results